Cargando…
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body com...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/ https://www.ncbi.nlm.nih.gov/pubmed/35745144 http://dx.doi.org/10.3390/nu14122414 |
_version_ | 1784734217104523264 |
---|---|
author | Volpe, Sara Lisco, Giuseppe Racaniello, Davide Fanelli, Margherita Colaianni, Valentina Vozza, Alfredo Triggiani, Vincenzo Sabbà, Carlo Tortorella, Cosimo De Pergola, Giovanni Piazzolla, Giuseppina |
author_facet | Volpe, Sara Lisco, Giuseppe Racaniello, Davide Fanelli, Margherita Colaianni, Valentina Vozza, Alfredo Triggiani, Vincenzo Sabbà, Carlo Tortorella, Cosimo De Pergola, Giovanni Piazzolla, Giuseppina |
author_sort | Volpe, Sara |
collection | PubMed |
description | Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter. |
format | Online Article Text |
id | pubmed-9227575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92275752022-06-25 Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study Volpe, Sara Lisco, Giuseppe Racaniello, Davide Fanelli, Margherita Colaianni, Valentina Vozza, Alfredo Triggiani, Vincenzo Sabbà, Carlo Tortorella, Cosimo De Pergola, Giovanni Piazzolla, Giuseppina Nutrients Article Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter. MDPI 2022-06-10 /pmc/articles/PMC9227575/ /pubmed/35745144 http://dx.doi.org/10.3390/nu14122414 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Volpe, Sara Lisco, Giuseppe Racaniello, Davide Fanelli, Margherita Colaianni, Valentina Vozza, Alfredo Triggiani, Vincenzo Sabbà, Carlo Tortorella, Cosimo De Pergola, Giovanni Piazzolla, Giuseppina Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title | Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title_full | Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title_fullStr | Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title_full_unstemmed | Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title_short | Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study |
title_sort | once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/ https://www.ncbi.nlm.nih.gov/pubmed/35745144 http://dx.doi.org/10.3390/nu14122414 |
work_keys_str_mv | AT volpesara onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT liscogiuseppe onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT racaniellodavide onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT fanellimargherita onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT colaiannivalentina onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT vozzaalfredo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT triggianivincenzo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT sabbacarlo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT tortorellacosimo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT depergolagiovanni onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy AT piazzollagiuseppina onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy |